SG11201810670VA - Use of mi r-198 in treating and diagnosing cutaneous squamous cell carcinoma - Google Patents
Use of mi r-198 in treating and diagnosing cutaneous squamous cell carcinomaInfo
- Publication number
- SG11201810670VA SG11201810670VA SG11201810670VA SG11201810670VA SG11201810670VA SG 11201810670V A SG11201810670V A SG 11201810670VA SG 11201810670V A SG11201810670V A SG 11201810670VA SG 11201810670V A SG11201810670V A SG 11201810670VA SG 11201810670V A SG11201810670V A SG 11201810670VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- singapore
- treating
- diaph1
- lamc2
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/122—Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 21 December 2017 (21.12.2017) WIP0 I PCT iii 111111111111111111111111111111111111111111111111111111111111111111111111111111111111111 (10) International Publication Number WO 2017/217935 Al (51) International Patent Classification: A61K 31/7088 (2006.01) A61P 35/00 (2006.01) G01N 33/48 (2006.01) (21) International Application Number: PCT/SG2017/050302 (22) International Filing Date: 14 June 2017 (14.06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 10201604845W 14 June 2016 (14.06.2016) SG (71) Applicant: AGENCY FOR SCIENCE, TECHNOLO- GY AND RESEARCH [SG/SG]; 1 Fusionopolis Way, #20-10 Connexis North Tower, Singapore 138632 (SG). (72) Inventors: SAMPATH, Prabha; c/o Institute of Medical Biology, 8A Biomedical Grove, #06-06, Singapore 138648 (SG). GOPINATH, Sundaram; c/o Institute of Medical Biology, 8A Biomedical Grove, #06-06, Singapore 138648 (SG). QUAH, Shan; c/o Institute of Medical Biology, 8A Biomedical Grove, #06-06, Singapore 138648 (SG). (74) Agent: SPRUSON & FERGUSON (ASIA) PTE LTD; P.O. Box 1531, Robinson Road Post Office, Singapore 903031 (SG). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) = (54) Title: USE OF MI R-198 IN TREATING AND DIAGNOSING CUTANEOUS SQUAMOUS CELL CARCINOMA FIG. 7 B-198 N N O (57) : The present invention refers to a method of treating a carcinoma by administration of one or more of an oligonucleotide comprising the sequence of miR-198 (SEQ ID NO: 1) or a functional part thereof, or an oligonucleotide which reduces expression of Follistatin-related protein 1 (FSTL1 ), Protein diaphanous homolog 1 (DIAPH1), Laminin subunit gamma-2 (LAMC2) or Uroki- nase-type plasminogen activator (PLAU). Preferably, the at least one or more oligonucleotides directed against FSTL1, DIAPH1, LAMC2 or PLAU is a shRNA or siRNA. Also provided is a method of determining the presence of carcinoma in a subject, comprising detecting and comparing the presence of miR-198 and/or at least one of FSTL1, DIAPH1, LAMC2 or PLAU, miR-181 a, epidermal growth factor (EGF), and epidermal growth factor receptor (EGFR), and comparing the detected levels with that in a control sample.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SG10201604845W | 2016-06-14 | ||
PCT/SG2017/050302 WO2017217935A1 (en) | 2016-06-14 | 2017-06-14 | Use of mi r-198 in treating and diagnosing cutaneous squamous cell carcinoma |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201810670VA true SG11201810670VA (en) | 2018-12-28 |
Family
ID=60664532
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202011388UA SG10202011388UA (en) | 2016-06-14 | 2017-06-14 | Use of mi r-198 in treating and diagnosing cutaneous squamous cell carcinoma |
SG11201810670VA SG11201810670VA (en) | 2016-06-14 | 2017-06-14 | Use of mi r-198 in treating and diagnosing cutaneous squamous cell carcinoma |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202011388UA SG10202011388UA (en) | 2016-06-14 | 2017-06-14 | Use of mi r-198 in treating and diagnosing cutaneous squamous cell carcinoma |
Country Status (5)
Country | Link |
---|---|
US (1) | US11053496B2 (en) |
EP (1) | EP3468565A4 (en) |
CN (1) | CN109789156B (en) |
SG (2) | SG10202011388UA (en) |
WO (1) | WO2017217935A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110736840A (en) * | 2019-10-21 | 2020-01-31 | 浙江大学 | Application of MMP7, CTSE or LAMC2 protein in preparation of intrahepatic cholangiocellular carcinoma diagnostic reagent |
US11976331B2 (en) | 2020-01-31 | 2024-05-07 | Castle Biosciences, Inc. | Methods of diagnosing and treating patients with cutaneous squamous cell carcinoma |
US11976333B2 (en) | 2020-01-31 | 2024-05-07 | Castle Biosciences, Inc. | Methods of diagnosing and treating patients with cutaneous squamous cell carcinoma |
CN111793605A (en) * | 2020-07-31 | 2020-10-20 | 北京中卫医正肿瘤医学研究有限公司 | Separation and extraction method of primary tumor cells of skin squamous carcinoma |
WO2022036245A1 (en) * | 2020-08-14 | 2022-02-17 | Castle Biosciences, Inc. | Methods of diagnosing and treating patients with cutaneous squamous cell carcinoma |
CN113235188B (en) * | 2021-05-10 | 2022-09-06 | 中国科学技术大学 | Fluorescent chitosan fiber for detecting miRNA-198 and preparation method thereof |
CN114015775A (en) * | 2021-11-10 | 2022-02-08 | 张波 | Molecular probe for treating head and neck squamous cell carcinoma and application thereof |
WO2023225618A2 (en) * | 2022-05-18 | 2023-11-23 | Yale University | Method for estimating a dynamic molecular program of a cell |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103993082B (en) * | 2006-01-05 | 2017-01-11 | 俄亥俄州立大学研究基金会 | Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer |
US20100310583A1 (en) * | 2007-01-31 | 2010-12-09 | Immune Disease Institute | Let-7 microrna and mimetics thereof as therapeutics for cancer |
US20090326053A1 (en) * | 2008-05-30 | 2009-12-31 | Trustees Of Boston University | Diagnostic uses of follistatin-like 1 |
KR101192297B1 (en) * | 2008-12-10 | 2012-10-17 | 한국생명공학연구원 | Novel Biomarkers Indicative of Liver Cancer and Their Uses |
WO2010093379A1 (en) | 2009-02-13 | 2010-08-19 | Fred Hutchinson Cancer Research Center | Gene expression profiling identifies genes predictive of oral squamous cell carcinoma and its prognosis |
CN102892898B (en) * | 2009-12-24 | 2016-03-09 | 复旦大学 | For the diagnostic kit containing microRNA biomarker and the method for diagnosis of hepatoma |
WO2011088226A2 (en) | 2010-01-13 | 2011-07-21 | Caris Life Sciences Luxembourg Holdings | Detection of gastrointestinal disorders |
US8987224B2 (en) * | 2011-08-05 | 2015-03-24 | Baylor College Of Medicine | MicroRNA-198 as a tumor suppressor in pancreatic cancer |
SG11201500615WA (en) * | 2012-07-27 | 2015-04-29 | Agency Science Tech & Res | Method of promoting wound healing |
CN103173450B (en) * | 2013-03-07 | 2015-02-18 | 新乡医学院第一附属医院 | Esophagus cancer postoperative early-stage recurrence and prognosis related miRNA marker and its application |
CN105586390B (en) * | 2014-10-23 | 2019-01-22 | 王辉云 | A kind of kit for Prognosis in Breast Cancer judgement |
-
2017
- 2017-06-14 WO PCT/SG2017/050302 patent/WO2017217935A1/en unknown
- 2017-06-14 US US16/310,395 patent/US11053496B2/en active Active
- 2017-06-14 CN CN201780049544.9A patent/CN109789156B/en active Active
- 2017-06-14 SG SG10202011388UA patent/SG10202011388UA/en unknown
- 2017-06-14 EP EP17813708.9A patent/EP3468565A4/en active Pending
- 2017-06-14 SG SG11201810670VA patent/SG11201810670VA/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3468565A1 (en) | 2019-04-17 |
EP3468565A4 (en) | 2020-08-19 |
CN109789156A (en) | 2019-05-21 |
US11053496B2 (en) | 2021-07-06 |
US20190330625A1 (en) | 2019-10-31 |
SG10202011388UA (en) | 2020-12-30 |
CN109789156B (en) | 2022-06-07 |
WO2017217935A1 (en) | 2017-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201810670VA (en) | Use of mi r-198 in treating and diagnosing cutaneous squamous cell carcinoma | |
SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
SG11201809913PA (en) | Methods for detecting target nucleic acids in a sample | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201408385TA (en) | Methods of detecting diseases or conditions | |
SG11201407486PA (en) | Compositions and methods for modulating utrn expression | |
SG11201805950UA (en) | Self-assembled nanostructures and separation membranes comprising aquaporin water channels and methods of making and using them | |
SG11201809252YA (en) | Methods for determining dpp3 and therapeutic methods | |
SG11201807912SA (en) | Vaccine against rsv | |
SG11201408153YA (en) | Prostate-specific membrane antigen antibody drug conjugates | |
SG11201900081QA (en) | Removing bubbles in a microfluidic device | |
SG11201901628XA (en) | Methods and compositions for spinal cord cells | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201900442PA (en) | Sorting of t lymphocytes in a microfluidic device | |
SG11201408383SA (en) | Methods of detecting diseases or conditions using circulating diseased cells | |
SG11201807593TA (en) | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers | |
SG11201810429UA (en) | Anti-cd19 antibody formulations | |
SG11201407988UA (en) | Process for improved opioid synthesis | |
SG11201810196RA (en) | Cancer treatments | |
SG11201908296VA (en) | Biomarkers for cancer therapeutics | |
SG11201809996QA (en) | Ribonucleic acid (rna) interactions | |
SG11201805755SA (en) | Methods of administering hepcidin | |
SG11201900912PA (en) | Novel fish pathogenic virus | |
SG11201804440XA (en) | Chemical reprogramming of human glial cells into neurons with small molecule cocktail | |
SG11201906778RA (en) | Improved methods for assessing risk of developing breast cancer |